cyrilzakka/clinical-trials huggingface dataset:
Real World Study on the Application of Appropriate Electrophysiological Technology in the Diagnosis and Treatment of Andrology Diseases in Northwest China

To carry out real world research on the application of electrophysiology and other suitable technologies in the prevention and treatment of male diseases in medical institutions at all levels in Northwest China, and establish a database for the prevention and treatment of male diseases in Northwest China, so as to provide a basis for the formulation of guidelines or consensus on the application of electrophysiology for the prevention and treatment of male diseases in China.


Eligibility Criteria:
Inclusion Criteria:

* Patient meets the diagnostic criteria of National Institutes of Health (NIH)Ⅲ type prostatitis;
* NIH-CPSI score \> 10;
* The symptoms lasted for more than 3 months and failed to respond to drug treatment for more than 1 month;
* Age ≥18 years old and ≤60 years old agrees and signs the informed consent;
* Those who did not receive other similar treatment regimens during treatment.

Exclusion Criteria:

* All kinds of bacterial infection caused by acute or chronic orchitis or epididymitis, acute or chronic prostatitis, lower urinary tract infection;
* Benign prostatic hyperplasia, prostate cancer, neurogenic bladder, urethral malformation or stricture and severe neurosis;
* For patients with local pain as the main manifestation, attention should be paid to the exclusion of other lesions in the lower abdomen, perineum, lsosacral sites, such as ureteral calculi, bladder calculi, inguinal hernia, pubis, varicocele, epididymitis, rectocolic diseases, lsodorsal myofascitis, etc.;
* Complicated with heart, brain, liver and hematopoietic system and other serious primary diseases, local skin infection or skin lesions in the treatment site;
* People who have metal implants in their bodies cannot cooperate, such as patients with mental illness.
* People who are allergic to the treatment of electrical stimulation or allergic to a variety of drugs.
Stentless Endoscopic Transnasal Transseptal Choanoplasty

Congenital choanal atresia is an abnormality of the posterior nasal passages resulting in complete or partial obstruction of the nasal airways. It has an incidence of 1: 5000 to 8000 live births, with a female predominance. 41% - 72% occur in conjunction with non-syndromic facial abnormalities such as arched palate, cleft lip, and auricular deformities. About 4% present as a component of chromosomally-based syndromes such as (coloboma, heart defect, atresia choanae, retarded growth, genital abnormality, and ear abnormality" and Treacher Collins syndromes.

Previous reports have described the ratio of bony to membranous choanal atresia as 9:1. However, a detailed review of computed tomography study combined with histopathological studies has shown mixed bony-membranous atresia in about 70% of cases and purely bony atresia in 30% of cases.

Common choanal atresia repair techniques include puncture and dilatation of the atretic area. Endoscopic drilling combined with dissection of the atretic plate and its surrounding structures has been introduced more recently. The approaches have been through transnasal, transpalatal, and transseptal routes. Each of which have experienced varying popularity through time. Regardless of the access route and repair technique used, re-stenosis is a common postoperative complication. To prevent re-stenosis and subsequent re-operation, many authors advocate meticulous preservation of mucosa for use as flaps, which in most cases are combined with postoperative stenting. However, stenting, is controversial

The surgical procedure is performed under general anesthesia. Preoperatively, cotton pledgets soaked in a solution of topical vasoconstrictors are placed against the nasal mucosa for topical decongestion. Local anesthesia is infiltrated into the nasal septum, the atretic plate, the middle turbinate, and the superolateral nasal wall. An endoscopic view of the surgical field is maintained at all times during the procedure using a 4-mm nasal endoscope with 0-degree or 30-degree visual angulation. Firstly, mucosa is elevated bilaterally from the underlying cartilaginous and bony septum on both sides. Then the posterior half of the septum including the vomer is removed using Blakesley forceps and a 1-mm or 2.5-mm diamond burr. After that, the flaps are fashioned using the preserved mucosa. At last, the flaps are secured in position with a thin layer of fibrin glue or gel foam. No packing or stenting is used. The patient is extubated immediately following the procedure and early oral feeding encouraged. The intended length of stay is overnight.

Eligibility Criteria:
Inclusion Criteria:

* • Denovo cases of unilateral congenital choanal atresia.

  * Revision cases of unilateral congenital choanal atresia.
  * Denovo cases of bilateral congenital choanal atresia.
  * Revision cases of bilateral congenital choanal atresia.

Exclusion Criteria:

* • Any associated medical comorbidity that contraindicates general anesthesia.

  * Refusal of enrollment in the research by care givers.
Neural Therapy Effect and Bilateral Tubal Ligation

The aim of this study is to evaluate the effect of nebulisation in patients with bilateral tubal ligation in the first postoperative year, the amount of dysmenorrhea, dyspareunia and menstrual bleeding, recurrent vaginitis and cystitis.

A retrospective analysis of bilateral tubal ligation with optional modified Pomeroy technique in the family planning unit and evaluation of the results of patients who underwent Neural Therapy during and postoperatively will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* patients who underwent bilateral tubal ligation with modified Pomeroy technique,
* Patients with dysmenore, dyspareunia and menstrual bleeding,

Exclusion Criteria:

* postoperative asymptomatic
* Additional treatments for pain and complaints
MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome

Considering the potential of mesenchymal stromal cells (MSCs) in the treatment of lung injuries by COVID-19, this pilot clinical trial evaluates the safety and potential efficacy of the cell therapy, administered intravenously, in patients with pneumonia associated with COVID-19-associated acute respiratory distress syndrome.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of COVID-19 confirmed by RT-PCR;
* Thorax CT image suggestive of viral pneumonia;
* Respiratory failure (SaO2 \<93% with O2 at 5L / min)
* Tracheal intubation (first 48 h);

Exclusion Criteria:

* Pregnancy or breastfeeding;
* Patients with a history of cancer, chemotherapy in the past 2 years;
* Life expectancy less than 6 months or in exclusive palliative care;
* Severe liver failure, with Child-Pugh score\> 12;
* High probability of death in the following 48 h;
* Previous renal failure: patients who were already on dialysis or patients with RFG \<30ml / min / 1.73 m2;
* Clinical or radiological suspicion of tuberculosis and bacterial pneumonia.
Functional Recovery and Pain Reduction Post-hydrodissection vs Rehabilitation in Patients With Carpal Tunnel Syndrome (Hydrocarpal)

This study pretend to evaluate the effectiveness of hydrodissection vs only rehabilitation in improving pain and function in patients with CTS.

This prospective, longitudinal, randomized in two groups clinical study pretend to evaluate the effectiveness of hydrodissection vs only rehabilitation in improving pain and function in patients with CTS, evaluated initially and at 4 and 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* men and women ≥18 years of age,
* members referred to and treated at the Physical Medicine and Rehabilitation Service of HGR N°1, IMSS Mérida Yucatán, and who had a clinical or electrophysiological diagnosis of carpal tunnel syndrome.

Exclusion Criteria:

* included a clinical or electrophysiological diagnosis of radiculopathy, plexopathy, polyneuropathy, or other peripheral neuropathy;
* current diagnosis of cancer, coagulopathy, thoracic outlet syndrome;
* active infectious process or current fracture in the thoracic limb;
* previous surgery for carpal tunnel release;
* inability to cooperate with filling out scales, physical examination, or infiltration, as clearly detailed.
AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects

This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy Japanese subjects.


Eligibility Criteria:
Inclusion Criteria:

* Healthy Japanese male and non-fertile female subjects aged ≥20 to ≤55 years with suitable veins for cannulation or repeated venepuncture.
* Body weight 45-90 kg and Body mass index (BMI) ≥18.0 and ≤27.0 kg/m2
* Clinically normal physical findings including supine blood pressure, pulse rate, orthostatic blood pressure, ECG, and laboratory assessments in relation to age, as judged by the Investigator.

Exclusion Criteria:

* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
* Any clinically significant illness/infection or medical/surgical procedure or trauma, as judged by the Principal Investigator, within 3 months of the first administration of investigational product.
* Frequent use of tobacco or other nicotine containing products. Frequent use is defined as smoking or consumption/intake of nicotine products more than two days per week during the last 12 weeks.
Pomegranate Supplementation and Well-Being Among Medical Students and Residents

Medical students and residents have high rates of mental distress and burnout related to the intellectual and time demands of their training. Research shows that physiological stress on the body can be a result of fatigue and high stress work, and is associated with experiences related to mental distress. Pomegranate is a fruit that is known to contain a variety of antioxidant substances that can reduce physiological stress. This study will look at the potential for pomegranate supplementation to reduce physiological stress and improve well-being in medical students and residents.

This is a pilot study to investigate the feasibility of conducting a randomized trial of pomegranate supplementation in medical students and residents, and to see whether there is evidence of an effect on reported emotional and physical well-being.

Phase 1 will be a pilot with 10 participants in which all will receive the pomegranate supplement for 28 days. In phase 2, we will randomize 40 participants (1:1) to receive either the pomegranate supplement or a placebo.

For both phases, we will measure self reported emotional and physical well-being using several questionnaires, and we will conduct laboratory testing for measures of oxidative stress and inflammatory biomarkers in blood, and for a metabolite of pomegranate in urine.

Eligibility Criteria:
Inclusion Criteria:

* First or second year medical student or first or second year resident listed at the University of Mississippi Medical Center

Exclusion Criteria:

* Pregnant or planning to become pregnant during the study period.
* Breast feeding.
* Unable to speak, understand, and read English.
* Taking chronic medications other than contraception
* Taking supplements (including over-the-counter multivitamins)
* Allergy to pomegranate or gelatin (gel-caps)
* Baseline scores on the DASS-21 that indicate a level of depressive or anxiety symptoms that is "severe" or "extremely severe." This would be a depression score greater than 10, or an anxiety score greater than 7.
Quality of Life After Radiofrequency Ablation of Pancreatic Cancer

A prospective clinical study evaluating quality of life (QoL) in pancreatic cancer patients treated with intraoperative radiofrequency ablation (RFA).


Eligibility Criteria:
Inclusion Criteria:

* histologically proved locally advanced or metastatic pancreatic cancer. Patients with histologically proved resectable pancreatic cancer with low Karnofsky index.

informed consent

Exclusion Criteria:

* cystic tumor

age under 18
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)

This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer not previously treated with chemotherapy
* Initiating Avastin in combination with chemotherapy

Exclusion Criteria:

* Contraindications, warnings and precautions for use as specified in the Avastin Summary of Product Characteristics
Patient Satisfaction and Postoperative Analgesia Between Subarachnoid Block With 2-chloroprocaine Versus General Anesthesia for Knee Arthroscopy

The study evaluates the efficacy of two different anesthetic techniques in patients undergoing unilateral knee arthroscopy. Participants will be randomized to receive either subarachnoid block with 2-chloroprocaine or general anesthesia plus intravenous fentanyl.

The study evaluates the efficacy of two different anesthetic techniques in patients undergoing unilateral knee arthroscopy. Participants will be randomized to receive either subarachnoid block with 2-chloroprocaine or general anesthesia plus intravenous fentanyl. The study evaluates pain scores, opioid utilization and patient satisfaction.

Eligibility Criteria:
Inclusion Criteria:

* Patients with ASA physical status classification of I, II, or III
* Patients without a current diagnosis of chronic pain or chronic opioid use for \> 1-month prior to knee arthroscopy
* Patients who are scheduled to undergo unilateral knee arthroscopy
* Patients do not have a contraindication to receiving regional anesthesia

Exclusion Criteria:

* Preexisting sensory or motor deficit in operative extremity
* Patients with a contraindication to general anesthesia
* Patient undergoing meniscal or ligamentous repair
Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients

The purpose of this study is to compare the efficacy and safety of pitavastatin with that of pravastatin in elderly patients

Following a wash-out dietary lead-in period, patients will receive either Preavastatin or Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing cholesterol levels.

Eligibility Criteria:
Inclusion Criteria:

* Males and postmenopausal females (aged 65 years and older
* Eligible, able to participate, have given informed consent
* Must have been following a restrictive diet
* Diagnosis of primary hypercholesterolemia or combined dyslipidemia
* Serum CK must be less than or equal to 1.5 x ULRR at 2 of 3 permitted evaluations between Week -4 and -1
* Agree to be available

Exclusion Criteria

* Homozygous familial hypercholesterolemia
* Conditions which may cause secondary dyslipidemia
* Uncontrolled diabetes mellitus (HbA1c \>8%).
* Any condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
* History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury
* Liver injury
* Impaired renal function
* Current obstruction of the urinary tract or difficulty in voiding due to mechanical as well as inflammatory conditions, which is likely to require intervention during the course of the study or is regarded as clinically meaningful
* Serum CK \>5 x ULRR without clinical explanation
* Uncontrolled hypothyroidism defined as TSH \>ULRR
* Any severe acute illness or severe trauma in the last 3 months prior to Visit 1
* Major surgery, 3 months prior to Visit 1
* Significant CVD prior to randomization
* Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response rate of \> 100 beats per minute at rest.
* Left ventricular ejection fraction \<0.25;
* History of symptomatic cerebrovascular disease
* Any other conditions at the discretion of the investigator
* Known HIV infection
* Poorly controlled or uncontrolled hypertension
* Prior or current known muscular or neuromuscular disease of any type;
* Neoplastic disease
* Drug abuse or continuous consumption of more than 65 mL pure alcohol per day
* Exposure to any investigational new drug within 30 days of study entry or ingestion of any drug known to be toxic to a major organ system
* Current or recent use of supplements known to alter lipid metabolism
* History of hypersensitivity to other HMG-CoA reductase inhibitors;
* Concomitant medication not permitted
* Resistant to lipid-lowering medications. Known hypersensitivity or intolerance to any lipid lowering agent
* Excessive obesity
* Any factor which makes regular clinic attendance in the morning impractical ---Signs of mental dysfunction or other factors likely to limit ability to cooperate with the study.
Anterior Plate Osteosynthesis of Fractures of the Lower Extremity of the Radius: Does the Systematic Use of Short Epiphysic Screws Limit the Posterior Protrusion of the Screws Without Compromising Stability

Anterior plate osteosynthesis of fractures of the lower extremity of the radius may be accompanied by tendinous complications : tenosynovitis of extensors or even tendon ruptures caused by the end of the epiphyseai screws.

The intraoperative measurements as well as the realization of the scopic pictures make it possible to estimate the length of the screws but the tendinous lesions remain frequent (5 to 15% according to the various series)

* Preoperative consultation

  * Oral information of the patient of the protocol and delivery of the written information note
  * Seeking patient's non-opposition to participating in the study
  * Inclusion of the patient
* Surgical procedure for distal radius fracture + immediate post-operative radiography

  * Intervention performed according to the usual practices of the service by the surgeon of the day without randomization
  * Radiography: 2 shots: face and wrist profile
* Control X-ray + consultation

  * Achieved at 3 weeks, 6 weeks and 3 months after the intervention
  * X-rays: 2 shots: face and wrist profile
* Control ultrasound o Realized at 3 months after the intervention

End of participation in the study after consultation of 3 months.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old
* Fracture (s) of extra joint distal radius with or without joint refend in the sagitta plane
* Osteosynthesis by anterior locked plate
* Patient who did not oppose his participation in this research

Exclusion Criteria:

* Distal radius fractures with joint refend frontal (posterior marginal)
the Effectiveness of a Weight Management Program in Patients Who Have Completed Treatment for Endometrial Cancer

The primary purpose of this study is to evaluate the effectiveness of a 12-month comprehensive weight management program on weight change in overweight/obese patients following treatment for endometrial cancer. During the study period, subjects will be monitored for recurrence during routine clinic visits A secondary exploratory purpose of this study will be to evaluate the gut microbiome in this intervention group and the changes that may occur while participating in a weight loss and weight management program.

All enrolled subjects will participate in the Profile weight loss and weight management program for a period of 12 months. They will work with a Profile lifestyle coach weekly to develop a personalized nutrition plan, discuss their activity, and lifestyle behavior as done with all Profile members. A comparison of similar retrospective chart reviews based on age, weight in pounds and stage of cancer will be conducted using the Electronic Medical Record (EMR). All enrolled subjects will collect and return a fecal specimen prior to beginning the weight management plan and again after 6 months of participation. The stool sample will be used to understand gut health.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age and older with a diagnosis of endometrial cancer
* No known metastatic disease
* Has completed all treatment for their endometrial cancer at least 2 months prior to enrollment.
* Has a BMI (Body Mass Index) of 30 or higher
* Ability to understand the purpose of study and willingness to sign consent
* Willingness to collect fecal specimens at the required time points
* Capable of following the dietary guidelines and instructions for the Profile weight management plan
* Agrees to sharing information between Profile and Sanford Research study personnel

Exclusion Criteria:

* BMI (Body Mass Index) less than 30
* Known metastatic disease
* Receiving treatment or expected to receive treatment for endometrial cancer or any other cancer
* Any psychological, familial, sociological conditions that the physician feels will interfere with medical follow-up and compliance on the study
* Taking insulin for diabetes (oral medications for diabetes allowed)
* Use of corticosteroids for a chronic medical condition
* Known liver disease
* Bowel or stomach disorders that the physician feels would interfere with Profile participation.
* Any history of malabsorption syndrome or substantial amounts of small bowel or stomach surgery that impairs nutrient absorption
Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study

Serum vitamin D levels in drug-induced non-immediate reactions

The study of serum vitamin D levels in patients presented with drug-induced non-immediate cutaneous adverse reactions compared to those in drug-tolerant control subjects

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with SJS/TEN, DRESS, AGEP, MPE, or FDE as mentioned above

Exclusion Criteria:

* Reactions from drugs with known strong genetic predispositions (allopurinol, carbamazepine, abacavir)
* Receiving vitamin D supplement
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.


Eligibility Criteria:
Key Inclusion Criteria:

* History of gout
* sUA \> 7 mg/dL
* Estimated Glomerular Filtration Rate (eGFR) ≥ 60 mL/min/1.73m2

Key Exclusion Criteria:

* Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
* History of cardiac abnormalities
* Active peptic ulcer disease or active liver disease
* History of kidney stones
* Allergy or intolerance to colchicine, febuxostat, and allopurinol